FORMA Therapeutics Announces Oncology Collaboration with Novartis
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
FORMA Therapeutics announced that it has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets in the field of oncology. Financial terms of the collaboration were not disclosed.
“FORMA is pleased to expand its relationship with Novartis beyond our existing agreement with the Novartis Option Fund,” said Steven Tregay, CEO of FORMA. “This collaboration provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery.”
“FORMA is pleased to expand its relationship with Novartis beyond our existing agreement with the Novartis Option Fund,” said Steven Tregay, CEO of FORMA. “This collaboration provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery.”
